Eshbal Functional Food Eyes Another Acquisition In North America

Credit: Julia Metkalova/Shutterstock

Eshbal Functional Food has signed a missive of intent to bargain a mostly liking successful US low-carb and gluten-free business Dare to Be Different Foods (D2BD).

According to Canada-listed Eshbal, nan acquisition is taxable to nan parties entering into a definitive agreement, including support by nan TSX Venture Exchange.

Based successful New York, D2BD was founded successful 2012 and manufactures low-carb and gluten-free stiff products, including crusts, crisps and gnocchi that are formulated pinch broccoli and cauliflower.

Eshbal plans to salary a operation of rate and shares for its planned 55% liking successful D2BD.

The institution said it whitethorn put up much shares successful itself if D2BD meets definite gross thresholds.

The magnitude of rate payments and number of Eshbal shares it issues will beryllium wished aft owed diligence is completed.

The news comes arsenic Eshbal, which is chiefly based successful Israel but has a North American agency successful Vancouver, has named Avi Markus arsenic its caller main commercialized serviceman of North America.

In nan caller role, Markus will oversee commercialized operations that see sales, distribution, partnerships and business development. His astir caller domiciled was astatine Canada-based infant-formula business Else Nutrition.

Earlier this month, Eshbal signed a missive of intent to get Gluten Free Nation, a Texas-based commercialized baker of gluten-free breadstuff and baked goods.

Eshbal said astatine nan clip that they are “excited astir nan imaginable to merge Gluten Free Nation’s merchandise statement and leverage its customer relationships to further grow Eshbal’s North American presence”.

While nan institution supplies foodservice and unit successful Israel, it precocious expanded into North America pursuing its reverse takeover pinch Canada-based Hakken Capital Corp. wherever it besides gained a listing connected nan TSX Venture Exchange.

According to Eshbal’s astir caller financial report, nan patient generated an yearly gross of astir $11.4m by nan extremity of 2024.